· 105-23-02 H

030

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)  Applicant(s): Nicolette   P		Docket No.  GA0118USC
Serial No. MAI 2 1 2002 Riling Date 10/041,977 January 9, 2002	Examiner Unassigned	Group Art Unit 1627
Invention: A METHOD TO IDENTIFYING CYTOTO	OXIC T-CELL EPITOPES	
I hereby certify that the following correspondence:		
A copy of the Notice to Comply with Requirements for l Amino Acid Sequence Disclosures (2 sheets); Statement Listing (10 sheets); and Return Postcard	Patent Applications Containing Nucle Under 37 C.F.R. 1.821(e) (2 sheets); P	otide Sequence and/or aper Copy of Sequence
(Identify type	of correspondence)	
is being deposited with the United States Postal Servi		
May 21, 2002 (Date)		
	TARYN ANTALES  (Typed or Printed Name of Person Mailing  (Signature of Person Mailing Corres  EL 408061868 US  ("Express Mail" Mailing Label N	Correspondence) pondence)

Note: Each paper must have its own certificate of mailing.



Patent

Our Docket: GAO118USC Customer No. 24536

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Art Unit: 1627
Charles A. Nicolette	
	Examiner:
Serial No.: 10/041,977	CERTIFICATE OF MAILING BY EXPRESSMAIL
	"EXPRESS MAIL" MAILING LABEL NO. EL 408061868 US
Filed: January 9, 2002	DATE OF DEPOSIT <u>May 21, 2002</u>
<b>,</b>	I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES
For: A METHOD FOR IDENTIFYING	POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO
CYTOTOXIC T CELL EPITOPES	L ADDRESSEE" SERVICE UNDER 37 CFR 1.10
CTTOTOMET CLEEP DITTOTES	ADDRESSED TO THE ASSISTANT
U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327	COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 2003 WASHINGTON, D.C. 2003
Arlington, Virginia 22202	Name Signature

## STATEMENT UNDER 37 C.F.R. §1.821(e)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 22, 2002 in connection with the above-identified patent application and further in accordance with 37 C.F.R. §1.821(e), Applicant brings to the Office's attention related patent application, U.S. Serial No. 08/989,195, filed December 11, 1997, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Applicant respectfully requests that the Sequence Listing in computer readable form supplied in compliance with 37 C.F.R. § 1.821 in the above-referenced parent application, *i.e.*, U.S. Serial No. 08/989,195, be made of written record and used in the examination of the subject application.

I hereby state, as required by 37 C.F.R. §1.821(e), that the content of the paper copy of the Sequence Listing submitted herewith in connection with the subject

In re: Nicolette USSN: 10/041,977 Filed: January 9, 2002

Page 2

application is identical to the computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR § 1.821 in parent application U.S. Serial No. 08/989,195, filed December 11, 1997, now U.S. Patent No. 6,338,945, issued January 15, 2002.

No fee is deemed necessary in connection with the filing of this Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

Date |

Deborah A. Dugan

Registration No. 37,315


Telephone: (508) 270-2598 Facsimile: (508) 872-5415

GENZYME CORPORATION

15 Pleasant Street Connector

P.O. Box 9322

Framingham, Massachusetts 01701-9322



24536 GENZYME CORPORATION LEGAL DEPARTMENT 15 PLEASANT ST CONNECTOR FRAMINGHAM, MA 01701-9322 CONFIRMATION NO. 7476
FORMALITIES LETTER

OC0000000076976991

Date Mailed: 03/22/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

06/05/2002 MPRASASD 00000003 071074 10041977

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE